Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Lowers Price Target to $730

Benzinga Newsdesk www.benzinga.com Negative 45.4%

Neg 45.4% Neu 0% Pos 0%

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and lowers the price target from $788 to $730.